Group 1 - The cosmetics sector experienced a rise of 1.12% on January 29, with Proya leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] - Key stocks in the cosmetics sector showed varied performance, with Tian Cai Ya up 2.81% and Jia Heng Jia Hua down 3.79% [2][3] Group 2 - The main capital flow in the cosmetics sector indicated a net outflow of 82.97 million yuan from institutional investors, while retail investors saw a net inflow of 82.61 million yuan [2] - Specific stock performances included Shanghai Jahwa with a net inflow of 17.61 million yuan from institutional investors, while other stocks like Marubi and LaFang experienced net outflows [3]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 33.34 [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of RMB 240 to 290 million in 2025, marking a turnaround from losses in the previous year. 2025 is viewed as a critical year for the company's strategic reform, focusing on core brands, brand building, online presence, and efficiency [1][6]. - The company has successfully developed three major products that have generated over RMB 100 million in sales each, demonstrating the effectiveness of its strategy combining category breakthroughs, major product cultivation, and marketing innovation [1][8]. - The company has adjusted its revenue forecasts for 2025-2027, now projecting revenues of RMB 6.407 billion, RMB 7.379 billion, and RMB 8.219 billion respectively, reflecting increases of 12.84%, 15.16%, and 11.38% [10]. Financial Performance - The company is projected to have a net profit of RMB 273.22 million in 2025, with an expected EPS of RMB 0.41. This is a significant recovery from a loss of RMB 833.09 million in 2024 [5][10]. - The company's return on equity (ROE) is expected to improve from -12.45% in 2024 to 3.93% in 2025, indicating a positive trend in profitability [5][10]. - The price-to-earnings (PE) ratio is projected to decrease from -17.32 in 2024 to 52.80 in 2025, reflecting a shift towards profitability [5][10]. Market Performance - The company's stock closed at RMB 21.46 as of January 28, with a market capitalization of RMB 14.426 billion. The stock has traded within a range of RMB 15.60 to RMB 28.92 over the past 52 weeks [2]. - The company has seen significant growth in its online sales channels, with notable performances on platforms like Douyin and Taobao, indicating strong brand momentum [7][9].

Company and Industry Summary Company: Shanghai Jahwa Key Points from the Earnings Forecast - **Earnings Forecast for 2025**: Shanghai Jahwa anticipates a net profit attributable to shareholders of 240-290 million yuan for 2025, with a non-recurring net profit of 38-56 million yuan, indicating a turnaround from losses in the previous year. The non-recurring gains are primarily attributed to changes in the fair value of financial assets and investment income [1][1][1] - **Q4 Performance Expectations**: For Q4, the company expects a net loss attributable to shareholders between -165 to -115 million yuan, and a non-recurring net loss between -193 to -175 million yuan. This performance is below expectations due to increased investments in brand building and losses from joint ventures such as Sephora and Pianzaihuang [1][1][1] - **Strategic Reforms Impact**: The strategic reforms implemented in 2025 have shown significant results, achieving a double-digit revenue growth target. Excluding the overseas Tomi Star business, domestic operations have experienced high double-digit growth [1][1][1] - **Profitability Metrics**: The estimated net profit margin for 2025 is approximately 4%, with a non-recurring net profit margin of about 1%, both indicating a return to profitability year-on-year. The gross margin is expected to improve significantly due to product mix optimization, while the sales expense ratio is slightly elevated due to strategic increases in brand building costs and a higher proportion of online and Douyin channel sales [1][1][1] 2026 Outlook - **Revenue Growth Strategy**: The company plans to focus on core products with a revenue target of continued double-digit growth. Domestic offline sales are expected to remain stable, while online sales are projected to grow by 30-40%. The Tomi Star business is anticipated to recover to single-digit growth, with profit growth expected to outpace revenue growth [1][1][1] - **Product Launches**: Key product launches for 2026 include: - **Yuze**: Following the success of the dry-sensitive cream, the company aims for the oil-sensitive cream to exceed 100 million yuan, along with new products like the special moisturizing cream and physical sunscreen. - **Baicaoji**: Expanding the mud mask category with high-end whitening and anti-aging products, targeting over 100 million yuan in sales. - **Liushen**: Upgrading the packaging of floral water and launching new shower gels and outdoor mosquito repellents [1][1][1] Additional Strategic Initiatives - **Establishment of Billion Yuan Product Club**: Each core brand will have an independent team responsible for billion-yuan products, with plans to recruit younger talent [2][2][2] - **In-house Douyin Team**: The Douyin content operation team has been internalized, significantly improving content operation efficiency [2][2][2] - **Profit Margin Improvement**: The expected gross margin has significant room for improvement due to the increased proportion of new products and efficiency gains from existing products. The sales expense ratio is anticipated to stabilize or slightly narrow due to improvements in single-channel efficiency and the mix of online and Douyin sales [2][2][2]

Company and Industry Summary Company: Shanghai Jahwa Key Financial Performance - For the year 2025, Shanghai Jahwa is projected to achieve a net profit attributable to shareholders of 240-290 million yuan, with a non-recurring net profit of 38-56 million yuan, marking a return to profitability year-on-year [1] - In Q4 2025, the company expects a net loss attributable to shareholders of -165 to -115 million yuan, and a non-recurring net loss of -193 to -175 million yuan, indicating a narrowing of losses compared to previous periods, albeit slightly below prior expectations [1] 2026 Goals - The company aims for revenue growth of over 10% in double digits for 2026, with profits expected to grow at a rate faster than revenue [1] Brand Investment Strategy - Significant investment in brand building during Q4 2025 is noted, aimed at fostering long-term growth [1] - New product launches such as Baicaojijian's Xian Cao Oil and Meijiajing's Propolis Repair Cream are part of the strategy to enhance brand visibility and establish a foundation for long-term development [1] Core Brand Development - The company plans to focus on three core brands: Baicaojijian, Yuze, and Liushen, with an emphasis on niche categories to create billion-yuan single products that drive sustained growth [2] Product Highlights - Baicaojijian's Big White Mud and Xian Cao Oil are rapidly growing and driving brand growth [3] - Yuze's Dry Sensitive Cream has surpassed 100 million yuan in sales in 2025, while the Oil Sensitive Cream is nearing the billion-yuan mark; a new product, "Special Moisturizing Cream," featuring exclusive fermented Artemisia oil essence, is set to launch in January 2026 [3] - Liushen's mosquito repellent products performed well in 2025, with plans to expand into niche markets for infants and outdoor scenarios to further modernize and digitize the brand [3] Market Performance - High-frequency data from Douyin indicates that the core brands are on a high growth trajectory, with Baicaojijian, Yuze, and Liushen showing year-on-year growth rates of 529%, 88%, and 39% respectively, leading to a combined GMV of 80 million yuan, a year-on-year increase of 262% [3] Investment Outlook - The rapid growth of single products is seen as a validation of the company's product development capabilities and the efficiency improvements following organizational adjustments [3] - Future focus will be on the pace of improvement in the company's profitability [3]

Core Viewpoint - The IPO application of HBN, a domestic skincare brand, signifies a shift in the beauty industry towards a focus on sustainable product innovation and core technological barriers, moving away from mere GMV growth and marketing volume [7] Group 1: Company Overview - HBN's parent company, Shenzhen Hujia Technology (Group) Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to be the "first stock of true efficacy skincare" [1] - The company has established a rigorous efficacy verification system and is the only skincare brand in China to conduct real-person efficacy testing on all its products through an international authority [5] Group 2: Financial Performance - HBN's revenue is projected to grow from 1.948 billion yuan in 2023 to 2.083 billion yuan in 2024, with a 10.2% increase in the first three quarters of 2025, reaching 1.514 billion yuan [3] - The net profit is expected to rise significantly from 39 million yuan in 2023 to 129 million yuan in 2024, and has already reached 145 million yuan in the first three quarters of 2025, with the net profit margin increasing from approximately 2% to nearly 10% [3] Group 3: User Engagement - HBN has accumulated over 4.6 million repeat customers, with average repurchase rates of 35.4% on Tmall and 44.0% on Douyin, significantly higher than the industry average of 20% [3] - The success of HBN's high repurchase rates is attributed to its strong product matrix, including top-selling items like the α-arbutin essence and caffeine eye cream, which have consistently ranked first in their categories [3] Group 4: Research and Development - HBN has made substantial investments in R&D, with a focus on building a comprehensive research chain covering basic research, raw material innovation, and efficacy validation [4] - The company has published 50 SCI papers, ranking first among domestic skincare brands, and has successfully registered four new self-developed cosmetic raw materials, placing third in the domestic skincare brand category [4] Group 5: Market Trends - The market is shifting towards "scientific-driven growth," with a focus on effective skincare products that address specific skin issues, indicating a move away from generalized marketing concepts [7] - HBN's approach demonstrates that long-term investment in research can build "hard power" and drive high-quality growth and user trust, providing a viable path for domestic beauty brands to compete and move upscale [7]

Core Insights - The A-share market showed mixed performance with the Shanghai Composite Index rising by 0.27% and the Shenzhen Component Index increasing by 0.09%, while the ChiNext Index fell by 0.57%. The total trading volume in the Shanghai and Shenzhen markets reached 29,650.88 billion yuan [1][7] - In the industry sector, non-ferrous metals, oil and petrochemicals, and coal led the gains, while sectors such as comprehensive, media, and national defense and military industry lagged behind. Concept sectors like gold, lead, and zinc saw significant increases, while monkeypox, cell immunotherapy, and newly listed tech stocks experienced declines [1][7] Important News - The Federal Reserve maintained its benchmark interest rate at 3.50%-3.75%, following three consecutive rate cuts of 25 basis points. This decision aligns with market expectations. The Fed noted signs of stabilization in the unemployment rate, while inflation remains relatively high, and economic uncertainty persists [2][8] Industry Analysis - The media industry experienced a strong performance in 2025, with the Shenwan Media sector rising by 27.17%, ranking ninth among Shenwan's first-level industries and outperforming the CSI 300 Index. The industry valuation (PE-TTM) has shown fluctuations but remains above the average level of the past seven years. Revenue and net profit for the first three quarters of 2025 showed steady growth, with year-on-year increases in Q3 [9][10] - The dual focus on IP and AI is reshaping the media industry. As consumer preferences shift from "functional" to "emotional value," there is a growing market for IP content and its commercialization. AI is recognized as a transformative technology with vast potential across various media sub-industries, driving new market developments [9][12] Investment Highlights - IP is categorized into content-based and image-based types, both of which can interchange to explore higher value and enhance commercialization through derivative products. Content-based IP includes literary and film adaptations, while image-based IP focuses on recognizable visual symbols [10][11] - The market for IP derivatives is experiencing explosive growth, driven by the rise of Generation Z consumers and the popularity of "emotional value" economics. Key product categories include collectibles and toys, which resonate with younger audiences' social and entertainment needs [12] - AI applications are expanding across multiple media sectors, enhancing content production efficiency and reducing costs. In gaming, AI is revolutionizing narrative and gameplay experiences, while in advertising, traditional marketing models are being restructured to adapt to new consumer information-seeking behaviors [14][13]

Core Viewpoint - The article highlights ongoing violations in the sale of special purpose cosmetics, particularly in the categories of hair growth, hair removal, breast enhancement, body shaping, and deodorants, despite a ban effective from January 1, 2026, on products with expired administrative licenses [1][6]. Group 1: Regulatory Changes - As of January 1, 2026, the five-year transition period for special purpose cosmetics will end, prohibiting the production, import, and sale of products with expired licenses [1]. - The article emphasizes that the National Medical Products Administration has not approved the efficacy claims of products associated with expired licenses, which raises concerns about consumer safety [2][6]. Group 2: Market Violations - Multiple products, including "依莲花" and "碧芙婷" body shaping creams, are being sold using expired licenses as a marketing tool, misleading consumers about their safety and efficacy [2][3]. - Various online stores are found to be using the same expired license "国妆特字G20200209" to promote different body shaping products, indicating a widespread issue of regulatory non-compliance [2][3]. Group 3: Misleading Claims - Some ordinary cosmetics are being marketed with false claims of body shaping and fat-burning effects, despite their actual registered functions being limited to moisturizing [4][5]. - The article details specific instances where products are advertised with claims that do not match their official registration, such as a product claiming to provide body shaping benefits while its actual registered efficacy is only for moisturizing [5]. Group 4: Consumer Awareness - The article urges consumers to verify the registration numbers and efficacy claims of cosmetics through the National Medical Products Administration's website or regulatory apps to ensure safety [6].

Group 1: New Consumption - Beauty Industry Insights - The GMV of cosmetics on WeChat Video Account is projected to reach 12.18 billion yuan in 2025, with domestic brands expected to dominate the channel [5][6] - In 2025, domestic brands are anticipated to hold an 80.4% market share on WeChat Video Account, with top brands like Zheng Mingming and Lin Qingxuan leading the sales [6][7] - Skincare products are expected to capture 68.9% of the market share in the WeChat Video Account channel, indicating a higher premium potential compared to other categories [6][7] Group 2: WeChat Video Account as a Competitive Platform - WeChat Video Account is seen as a new battleground for beauty brands, offering a unique advantage by integrating public and private domains, allowing brands to retain users for long-term engagement [7] - The beauty-related voice volume in the WeChat ecosystem reached 10.39 million from October 2024 to September 2025, marking a 48% year-on-year growth, with video account voice volume increasing by 121.9% [7] - The platform's clear commercialization logic and empowerment system provide beauty brands with sustainable growth opportunities, making it crucial for brands to establish a presence on this platform [7] Group 3: Pharmaceutical Industry - Fuyuan Pharmaceutical Overview - Fuyuan Pharmaceutical, established in 1999 and listed in 2022, focuses on generic drugs and is expanding into innovative drugs, with a robust portfolio of 209 domestic drug registrations [13][14] - The company reported a revenue of 3.209 billion yuan from drug formulations in 2024, with a compound annual growth rate (CAGR) of 7.75% from 2019 to 2024, indicating stable growth [14][15] - Fuyuan is strategically investing in small nucleic acid innovative drugs, with 23 patents filed, and its core pipeline includes FY101, which is in Phase I clinical trials, targeting a large market of patients with dyslipidemia [15][16] Group 4: Financial Projections for Fuyuan Pharmaceutical - The company is expected to achieve net profits of 465 million yuan, 481 million yuan, and 520 million yuan from 2025 to 2027, with growth rates of -5%, 4%, and 8% respectively [16] - The current price-to-earnings (PE) ratios for these years are projected at 30X, 29X, and 27X, indicating a favorable valuation compared to peers [16]

Core Viewpoint - Shanghai Jahwa is expected to achieve a net profit of between 240 million to 290 million yuan for the year 2025, marking a turnaround from losses in the previous year, driven by growth in core business, improved gross margins, and increased non-recurring income [1] Group 1: Strategic Focus and Brand Development - 2025 is a critical year for Shanghai Jahwa's strategic reform, emphasizing "focusing on core brands, brand building, online presence, and efficiency," which has successfully driven a brand-driven growth model [1] - The company has launched several billion-yuan products and potential new products that have significantly enhanced the competitiveness of core brands and accelerated brand momentum [1][2] - The establishment of a billion-yuan product club in Q4 2025 aims to leverage brand resources and operational experience to create a matrix of blockbuster products [2] Group 2: Product Innovation and Market Response - Several new products have shown strong potential to become billion-yuan products, including the Six God refreshing fragrance shower gel and the second-generation Yuze dry-sensitive cream, which have successfully targeted young consumers [3] - The launch of the first high-concentration essence oil by the Baicaoji brand has topped sales charts on major e-commerce platforms, demonstrating the company's growing capability in product incubation [3][4] Group 3: Research and Development Enhancements - Shanghai Jahwa is committed to deepening research and development, focusing on skincare technology and raw material innovation, with the opening of the "Shanghai Jahwa Innovation Center - Synthetic Biology" in March 2025 [4] - The company has registered multiple new cosmetic raw materials and launched the first skin glycation level quantification and imaging device in the industry, filling a significant gap in non-invasive skin testing [4] Group 4: Efficiency and Supply Chain Innovations - The company has initiated an e-commerce supply chain innovation project to explore new paths for direct e-commerce factory dispatch, significantly shortening the distribution chain and enhancing efficiency [5] - In 2026, the company plans to continue its growth trajectory by focusing on a clear combination of "brand - blockbuster products - channels," with key brands like Yuze, Six God, and Baicaoji driving growth [5][6]

Core Insights - The article highlights the competitive landscape of the Chinese beauty market, where domestic brands like Han Shu are striving to establish a long-term presence against international giants by focusing on quality and innovation rather than short-term trends [1][2]. Group 1: Long-term Strategy - Han Shu emphasizes a long-term approach, requiring investments measured over a decade, contrasting with the prevalent short-term strategies in the industry [1][2]. - The brand has committed to self-research and production, diverging from the common practice of relying on outsourcing and marketing [2][3]. - Since 2021, Han Shu has maintained an annual R&D investment of over 100 million yuan, projected to reach 180 million yuan in 2024, accounting for 2.7% of its revenue [2]. Group 2: Research and Development - Han Shu established its R&D center in 2003, marking a significant step in its long-term development strategy [2]. - In 2016, Han Shu became the first domestic beauty brand to set up a large-scale R&D center overseas, aiming to integrate global cutting-edge technology into its product offerings [2]. - The brand has developed an "open innovation R&D platform" to foster collaboration across various fields, partnering with institutions like Shanghai Jiao Tong University and Chongqing Traditional Chinese Medicine Hospital [2][3]. Group 3: Product Quality and Manufacturing - Han Shu's smart factory, the first AI-driven cosmetics facility in the domestic market, represents a significant investment of over 1.2 billion yuan, with 400 million yuan allocated for smart equipment upgrades [4][5]. - The factory employs advanced technologies such as AGV vehicles and industrial robots to enhance production efficiency and ensure product quality through rigorous testing [5]. - The integrated production and research model creates a robust quality assurance system, preventing potential issues in product formulation [5]. Group 4: Future Vision and Brand Expansion - Han Shu aims to expand from a skincare-focused brand to a comprehensive beauty brand covering skincare, makeup, men's grooming, and hair care, aspiring to be recognized as a "good brand" with quality products [6]. - The company is establishing a sustainable brand philanthropy system, including the creation of the Han Shu Charity Foundation to address social issues and promote long-term community engagement [6]. - Han Shu plans to take a proactive role in industry standards and scientific communication, transitioning from a market participant to a leader in high-quality development [6][7].